Share the post "FII Data: Stock Market today Insights for 05 Aug 2024"
Foreign Investment(buy/sell) Trends of Today’s: Global Events of Shah Metacorp , Jubilant Pharmova .
The latest financial figures for Shah Metacorp Limited indicate a strong performance. The company achieved net sales of ₹462.90 million and total income of ₹463.19 million for the quarter. Expenditure was ₹436.81 million, resulting in a net profit of ₹233.38 million. Earnings per Share (EPS) for continuing operations stood at ₹0.56. The report also shows other income of ₹0.29 million, finance costs of ₹0.06 million, and employee benefit expenses of ₹2.79 million. Depreciation and amortization expenses totaled ₹8.31 million. Current tax expense was ₹0.00 million and deferred tax expense was ₹41.22 million. Total comprehensive income for the period was ₹233.38 million, with other comprehensive income net of taxes at ₹0.00 million.
Currently valued at ₹217 crore, the company's stock price is ₹5.12. It has seen a price range of ₹7.40 / 2.51 over time. The stock's Price-to-Earnings (P/E) ratio is notably high at 41.8, implying a strong valuation. The book value per share is ₹1.37 and the dividend yield is 0.00%. ROCE is recorded at 25.8%, and ROE stands at 61.0%. The company maintains a very low debt-to-equity ratio of 0.64, though it has a negative net cash flow of ₹-28.3 crore. The Piotroski score of 6.00 and the Graham Number of ₹4.40 suggest some caution, while the Price-to-Book (P/B) ratio of 3.74 reflects a premium valuation.
For Jubilant Pharmova Limited, the latest financial data showcases impressive results. The company reported net sales of ₹17,317.00 million and total income of ₹17,457.00 million for the quarter. Expenditure was ₹16,419.00 million, resulting in a net profit of ₹4,818.00 million. EPS for continuing operations was ₹30.44. Additional financial details include other income of ₹140.00 million, finance costs of ₹710.00 million, and employee benefit expenses of ₹5,529.00 million. Depreciation and amortization expenses were ₹907.00 million. Current tax was ₹261.00 million and deferred tax amounted to ₹-82.00 million. Total comprehensive income for the period was ₹4,779.00 million, with other comprehensive income net of taxes at ₹-39.00 million.
The company's market cap is ₹19,424 crore, with a stock price of ₹1,220. The historical stock range has been between ₹1,247 / 319. Its Price-to-Earnings (P/E) ratio of 83.0 indicates a high valuation. The book value per share is ₹341, and it has a dividend yield of 0.41%. The ROCE is 6.74% and ROE is 0.76%. With a very low debt-to-equity ratio of 0.67, the company is minimally leveraged. However, it reports a negative net cash flow of ₹-57.5 crore. The Piotroski score of 8.00 and the Graham Number of ₹516 show mixed financial indicators, while the Price-to-Book (P/B) ratio of 3.58 suggests the stock is trading at a premium.
In the most recent financial analysis for Bajaj Consumer Care Limited, key metrics demonstrate a solid performance. The net sales reached ₹2,411.78 million, with total income amounting to ₹2,521.83 million. Expenditure was recorded at ₹2,061.60 million, resulting in a net profit of ₹379.82 million. EPS figures for continuing operations are ₹2.66. Other notable figures include other income of ₹110.04 million, finance costs of ₹1.65 million, and employee benefit expenses totaling ₹270.30 million. Depreciation and amortization expenses were ₹22.27 million, with current tax at ₹80.41 million and deferred tax at ₹0.00 million. The total comprehensive income for the period was ₹379.82 million, and other comprehensive income net of taxes was ₹0.00 million.
The company's market cap is ₹3,690 crore, with a stock price of ₹258. The historical stock range has been between ₹289 / 200. Its Price-to-Earnings (P/E) ratio of 25.2 indicates a high valuation. The book value per share is ₹58.2, and it has a dividend yield of 1.16%. The ROCE is 22.8% and ROE is 18.8%. With a very low debt-to-equity ratio of 0.01, the company is minimally leveraged. However, it reports a negative net cash flow of ₹8.76 crore. The Piotroski score of 8.00 and the Graham Number of ₹116 show mixed financial indicators, while the Price-to-Book (P/B) ratio of 4.44 suggests the stock is trading at a premium.
In the most recent financial analysis for Aavas Financiers Limited, key metrics demonstrate a solid performance. The net sales reached ₹5,423.88 million, with total income amounting to ₹5,425.55 million. Expenditure was recorded at ₹3,816.07 million, resulting in a net profit of ₹1,261.01 million. EPS figures for continuing operations are ₹15.93. Other notable figures include other income of ₹1.67 million, finance costs of ₹2,351.74 million, and employee benefit expenses totaling ₹915.52 million. Depreciation and amortization expenses were ₹85.08 million, with current tax at ₹373.26 million and deferred tax at ₹-24.78 million. The total comprehensive income for the period was ₹1,261.01 million, and other comprehensive income net of taxes was ₹0.00 million.
With a market capitalization of ₹14,846 crore, the company’s stock is currently priced at ₹1,876. The historical trading range of the stock is ₹1,979 / 1,307. The P/E ratio is remarkably high at 30.3, suggesting a significant valuation. The book value stands at ₹477, and the dividend yield is 0.00%. The Return on Capital Employed (ROCE) is 9.91%, and the Return on Equity (ROE) is 13.9%. The debt-to-equity ratio is very low at 3.29, though the company shows a negative net cash flow of ₹-157 crore. The Piotroski score is 2.00, with the Graham Number pegged at ₹816. The Price-to-Book (P/B) ratio of 3.93 highlights a premium valuation.
| Company Logo | Company | Client Name | Buy/Sell | Qty Traded | Price | Trader Name |
|---|---|---|---|---|---|---|
 |
Shah Metacorp | Citadel Securities India Markets Private | Buy | 2M | 6.17 | Na |
 |
Jubilant Pharmova | East Bridge Capital Master Fund I | Buy | 1M | 851.00 | East Bridge Capital Master Fund |
 |
Bajaj Consumer Care | Goldman Sachs Funds – Goldman Sachs India Equity Portfolio | Sell | 2M | 256.02 | Quant Mutual Fund |
 |
Aavas Financiers | Smallcap World Fund Inc | Buy | 501K | 1630.00 | Na |
The 2M shares of Shah Metacorp have been purchased by the by Citadel Securities India Markets Private through Foreign Investments at a price of ₹6.17 per share.
The 1M shares of Jubilant Pharmova have been purchased by the by East Bridge Capital Master Fund I through Foreign Investments at a price of ₹851.00 per share and it is sold by East Bridge Capital Master Fund at a price of ₹851.00 per share.
The 2M shares of Bajaj Consumer Care have been sold by the by Goldman Sachs Funds – Goldman Sachs India Equity Portfolio through Foreign Investments at a price of ₹256.02 per share and it is purchased by Quant Mutual Fund at a price of ₹256.02 per share.
The 501K shares of Aavas Financiers have been purchased by the by Smallcap World Fund Inc through Foreign Investments at a price of ₹1630.00 per share.
The 1M shares of Jubilant Pharmova have been purchased by the by East Bridge Capital Master Fund I through Foreign Investments at a price of ₹851.00 per share and it is sold by East Bridge Capital Master Fund at a price of ₹851.00 per share.
Shah Metacorp Limited
462.90
Net Sales
233.38
Net Profit
463.19
Total Income
436.81
Expenditure
5.12
Current Price
217
Market Cap
The latest financial figures for Shah Metacorp Limited indicate a strong performance. The company achieved net sales of ₹462.90 million and total income of ₹463.19 million for the quarter. Expenditure was ₹436.81 million, resulting in a net profit of ₹233.38 million. Earnings per Share (EPS) for continuing operations stood at ₹0.56. The report also shows other income of ₹0.29 million, finance costs of ₹0.06 million, and employee benefit expenses of ₹2.79 million. Depreciation and amortization expenses totaled ₹8.31 million. Current tax expense was ₹0.00 million and deferred tax expense was ₹41.22 million. Total comprehensive income for the period was ₹233.38 million, with other comprehensive income net of taxes at ₹0.00 million.
Currently valued at ₹217 crore, the company's stock price is ₹5.12. It has seen a price range of ₹7.40 / 2.51 over time. The stock's Price-to-Earnings (P/E) ratio is notably high at 41.8, implying a strong valuation. The book value per share is ₹1.37 and the dividend yield is 0.00%. ROCE is recorded at 25.8%, and ROE stands at 61.0%. The company maintains a very low debt-to-equity ratio of 0.64, though it has a negative net cash flow of ₹-28.3 crore. The Piotroski score of 6.00 and the Graham Number of ₹4.40 suggest some caution, while the Price-to-Book (P/B) ratio of 3.74 reflects a premium valuation.
Jubilant Pharmova Limited
17,317.00
Net Sales
4,818.00
Net Profit
17,457.00
Total Income
16,419.00
Expenditure
1,220
Current Price
19,424
Market Cap
For Jubilant Pharmova Limited, the latest financial data showcases impressive results. The company reported net sales of ₹17,317.00 million and total income of ₹17,457.00 million for the quarter. Expenditure was ₹16,419.00 million, resulting in a net profit of ₹4,818.00 million. EPS for continuing operations was ₹30.44. Additional financial details include other income of ₹140.00 million, finance costs of ₹710.00 million, and employee benefit expenses of ₹5,529.00 million. Depreciation and amortization expenses were ₹907.00 million. Current tax was ₹261.00 million and deferred tax amounted to ₹-82.00 million. Total comprehensive income for the period was ₹4,779.00 million, with other comprehensive income net of taxes at ₹-39.00 million.
The company's market cap is ₹19,424 crore, with a stock price of ₹1,220. The historical stock range has been between ₹1,247 / 319. Its Price-to-Earnings (P/E) ratio of 83.0 indicates a high valuation. The book value per share is ₹341, and it has a dividend yield of 0.41%. The ROCE is 6.74% and ROE is 0.76%. With a very low debt-to-equity ratio of 0.67, the company is minimally leveraged. However, it reports a negative net cash flow of ₹-57.5 crore. The Piotroski score of 8.00 and the Graham Number of ₹516 show mixed financial indicators, while the Price-to-Book (P/B) ratio of 3.58 suggests the stock is trading at a premium.
Bajaj Consumer Care Limited
2,411.78
Net Sales
379.82
Net Profit
2,521.83
Total Income
2,061.60
Expenditure
258
Current Price
3,690
Market Cap
In the most recent financial analysis for Bajaj Consumer Care Limited, key metrics demonstrate a solid performance. The net sales reached ₹2,411.78 million, with total income amounting to ₹2,521.83 million. Expenditure was recorded at ₹2,061.60 million, resulting in a net profit of ₹379.82 million. EPS figures for continuing operations are ₹2.66. Other notable figures include other income of ₹110.04 million, finance costs of ₹1.65 million, and employee benefit expenses totaling ₹270.30 million. Depreciation and amortization expenses were ₹22.27 million, with current tax at ₹80.41 million and deferred tax at ₹0.00 million. The total comprehensive income for the period was ₹379.82 million, and other comprehensive income net of taxes was ₹0.00 million.
The company's market cap is ₹3,690 crore, with a stock price of ₹258. The historical stock range has been between ₹289 / 200. Its Price-to-Earnings (P/E) ratio of 25.2 indicates a high valuation. The book value per share is ₹58.2, and it has a dividend yield of 1.16%. The ROCE is 22.8% and ROE is 18.8%. With a very low debt-to-equity ratio of 0.01, the company is minimally leveraged. However, it reports a negative net cash flow of ₹8.76 crore. The Piotroski score of 8.00 and the Graham Number of ₹116 show mixed financial indicators, while the Price-to-Book (P/B) ratio of 4.44 suggests the stock is trading at a premium.
Aavas Financiers Limited
5,423.88
Net Sales
1,261.01
Net Profit
5,425.55
Total Income
3,816.07
Expenditure
1,876
Current Price
14,846
Market Cap
In the most recent financial analysis for Aavas Financiers Limited, key metrics demonstrate a solid performance. The net sales reached ₹5,423.88 million, with total income amounting to ₹5,425.55 million. Expenditure was recorded at ₹3,816.07 million, resulting in a net profit of ₹1,261.01 million. EPS figures for continuing operations are ₹15.93. Other notable figures include other income of ₹1.67 million, finance costs of ₹2,351.74 million, and employee benefit expenses totaling ₹915.52 million. Depreciation and amortization expenses were ₹85.08 million, with current tax at ₹373.26 million and deferred tax at ₹-24.78 million. The total comprehensive income for the period was ₹1,261.01 million, and other comprehensive income net of taxes was ₹0.00 million.
With a market capitalization of ₹14,846 crore, the company’s stock is currently priced at ₹1,876. The historical trading range of the stock is ₹1,979 / 1,307. The P/E ratio is remarkably high at 30.3, suggesting a significant valuation. The book value stands at ₹477, and the dividend yield is 0.00%. The Return on Capital Employed (ROCE) is 9.91%, and the Return on Equity (ROE) is 13.9%. The debt-to-equity ratio is very low at 3.29, though the company shows a negative net cash flow of ₹-157 crore. The Piotroski score is 2.00, with the Graham Number pegged at ₹816. The Price-to-Book (P/B) ratio of 3.93 highlights a premium valuation.
